Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Renovo ends Prevascar development

Renovo ends Prevascar development

Renovo (LON:RNVO) today confirmed that it will now perform any further work on Prevascar following the completion of a clinical trial.

The company says that it will continue to focus on its merger and acquisition plans and its share buy-back programme as a way to enhance shareholder value.

The clinical trial results follow the disappointing results of the Juvista trial in February 2011. Subsequently, Renovo’s remaining trials which had already been contracted had continued.

Today, Renovo reported that 56 patients were enrolled in the trial of the Prevascar scar treatment. It said there was a ‘small but significant’ reduction in scar width compared to placebo after one month, however by month 12 there was in fact a ‘small but significant’ improvement in the placebo scar width compared to Prevascar. 

Meanwhile, most other assessments showed no difference between treatments. 

In November, Renove told investors that it was considering all options to maximise value including acquisitions and mergers of external companies.

 

View full RNVO profile View Profile

Renovo Group Plc Timeline

Newswire
December 13 2012
Newswire
April 16 2012
Newswire
December 15 2011
Newswire
November 18 2011

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use